De novo mutations in the genes’ DHDDS encoding dehydrodolichol diphosphate synthetase (DHDDS) and NUS1 (nuclear undecaprenyl pyrophosphate synthase 1) encoding the Nogo-B receptor (NgBR) cause neurodevelopmental syndromes largely characterised by epilepsy and movement abnormalities including mild ataxia, myoclonus, and dystonia [1,2,3]. Here, NUS1 is linked to epilepsy.